ARTICLE | Clinical News
Ranolazine: Started Phase III
January 8, 2001 8:00 AM UTC
CV Therapeutics Inc. (CVTX), Palo Alto, Calif. Product: Ranolazine Business: Cardiovascular Therapeutic category: Metabolism Target: NA Description: Anti-ischemic agent; partial inhibitor of fatty aci...